Drugs / erlotnib
Trials 0
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Comparator or background therapy1 trial | ||||||
| Phase 1 | NCT02071862 Background | Feb 2014 → Mar 2019 | gastrointestinal stromal tumor, mesothelioma, non-small cell lung carcinoma, renal cell carcinoma +1 | Calithera Biosciences, Inc | Completed | No outcome recorded |
Evidence & citations 1 cited value
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | erlotnib | “CB-839 in combination with standard dose erlotnib” NCT02071862 ↗ |